LRFN5

Summary

LRFN5 (leucine rich repeat and fibronectin type III domain containing 5, HGNC:20360) is a protein-coding gene on chromosome 14q21.1, encoding Leucine-rich repeat and fibronectin type-III domain-containing protein 5 (Q96NI6). Cell adhesion molecule that mediates homophilic cell-cell adhesion in a Ca(2+)-independent manner.

This gene encodes a protein that belongs to the leucine-rich repeat and fibronectin type III domain-containing family of proteins. A similar protein in mouse, a glycosylated transmembrane protein, is thought to function in presynaptic differentiation.

Source: NCBI Gene 145581 — RefSeq curated summary.

At a glance

• GWAS associations: 17
• Clinical variants (ClinVar): 103 total
• MANE Select transcript: NM_152447

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20360
Approved symbol	LRFN5
Name	leucine rich repeat and fibronectin type III domain containing 5
Location	14q21.1
Locus type	gene with protein product
Status	Approved
Aliases	FIGLER8, SALM5
Ensembl gene	ENSG00000165379
Ensembl biotype	protein_coding
OMIM	612811
Entrez	145581

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 8 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000298119, ENST00000553926, ENST00000554120, ENST00000554171, ENST00000555279, ENST00000935948, ENST00000935949, ENST00000935950, ENST00000955328, ENST00000955329

RefSeq mRNA: 4 — MANE Select: NM_152447 NM_001330106, NM_001346173, NM_001346175, NM_152447

CCDS: CCDS81800, CCDS9678

Canonical transcript exons

ENST00000298119 — 6 exons

Exon	Start	End
ENSE00001092594	41891250	41891962
ENSE00001092595	41886606	41888010
ENSE00001229115	41766854	41767029
ENSE00001818723	41606876	41608562
ENSE00003630388	41898917	41898960
ENSE00003639774	41904158	41904549

Expression profiles

Bgee: expression breadth ubiquitous, 195 present calls, max score 96.41.

FANTOM5 (CAGE): breadth broad, TPM avg 2.8464 / max 129.1825, expressed in 473 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
139395	0.6086	139
139388	0.5466	291
139393	0.5066	120
139389	0.4878	132
139394	0.2141	96
139390	0.1946	89
139392	0.1096	69
139396	0.1030	59
139391	0.0756	37

Top tissues by expression

257 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle temporal gyrus	UBERON:0002771	96.41	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.00	gold quality
Brodmann (1909) area 46	UBERON:0006483	90.61	gold quality
primary visual cortex	UBERON:0002436	89.85	gold quality
endothelial cell	CL:0000115	88.46	gold quality
superior frontal gyrus	UBERON:0002661	87.50	gold quality
occipital lobe	UBERON:0002021	87.27	gold quality
postcentral gyrus	UBERON:0002581	86.24	gold quality
parietal lobe	UBERON:0001872	85.85	gold quality
entorhinal cortex	UBERON:0002728	85.52	gold quality
buccal mucosa cell	CL:0002336	85.47	gold quality
prefrontal cortex	UBERON:0000451	84.42	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	84.03	gold quality
frontal cortex	UBERON:0001870	83.97	gold quality
cortical plate	UBERON:0005343	83.41	gold quality
sural nerve	UBERON:0015488	82.96	gold quality
neocortex	UBERON:0001950	82.93	gold quality
Brodmann (1909) area 9	UBERON:0013540	82.88	gold quality
cerebral cortex	UBERON:0000956	82.28	gold quality
oviduct epithelium	UBERON:0004804	81.93	gold quality
right frontal lobe	UBERON:0002810	80.88	gold quality
endocervix	UBERON:0000458	80.42	gold quality
substantia nigra pars compacta	UBERON:0001965	79.25	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.73	gold quality
anterior cingulate cortex	UBERON:0009835	78.62	gold quality
lateral nuclear group of thalamus	UBERON:0002736	78.59	gold quality
uterine cervix	UBERON:0000002	78.33	gold quality
temporal lobe	UBERON:0001871	78.28	gold quality
ectocervix	UBERON:0012249	77.92	gold quality
superior vestibular nucleus	UBERON:0007227	77.72	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	100.28
E-HCAD-25	yes	89.28
E-MTAB-5061	yes	13.45
E-GEOD-81608	yes	6.72
E-GEOD-81547	yes	6.48
E-ENAD-27	yes	5.41
E-ANND-3	yes	4.81
E-MTAB-8060	no	41.56

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

36 targeting LRFN5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-139-5P	99.80	69.50	1399
HSA-MIR-5002-5P	99.76	70.84	1763
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-494-3P	99.70	71.45	2795
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-29B-2-5P	99.67	68.98	1726
HSA-MIR-510-3P	99.54	70.06	2965
HSA-MIR-7159-5P	99.53	72.12	2472
HSA-MIR-3609	99.52	69.89	2587
HSA-MIR-548AH-5P	99.52	69.73	2626
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-520E-5P	99.27	68.90	1513
HSA-MIR-5693	99.24	66.67	1106
HSA-MIR-4426	99.17	66.74	1949
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-3688-5P	99.12	69.67	1091
HSA-MIR-622	98.99	66.48	1050
HSA-MIR-3150B-3P	98.81	67.21	1728
HSA-MIR-583	98.71	67.44	1791
HSA-MIR-3689A-5P	98.35	70.12	1049
HSA-MIR-3689B-5P	98.35	70.12	1049
HSA-MIR-3689E	98.35	70.12	1049
HSA-MIR-3689F	98.35	70.08	1052
HSA-MIR-4662B	98.33	66.37	1163
HSA-MIR-4647	98.30	66.41	1139
HSA-MIR-2681-3P	98.18	65.28	577
HSA-MIR-4768-3P	98.16	66.02	2330

Literature-anchored findings (GeneRIF, showing 9)

• Expression of SALM family proteins SALM3 and SALM5 in nonneural and neural cells induces both excitatory and inhibitory presynaptic differentiation in contacting axons. (PMID:20410109)
• SALM5/Lrfn5, has recently been implicated in severe progressive autism and familial schizophrenia, pointing to the clinical importance of SALMs.[review] (PMID:21736948)
• Presynaptic differentiation induced by protein tyrosine phosphatase receptor type D (PTPdelta)-leucine rich repeat and fibronectin type III domain containing 5 (SALM5) requires the dimeric property of SALM5. (PMID:29348429)
• In the 2:2 heterotetrameric SALM5/PTPdelta complex, a SALM5 dimer bridges two separate PTPdelta molecules. (PMID:29348579)
• we found that chr14.232.a increases expression of LRFN5 in his fibroblasts. Reduced expression of LRFN5 in fibroblasts should be interpreted with caution as these cells might not be representative of expression in brain cells, which are involved in the neurodevelopmental phenotype. (PMID:31152157)
• Identification of novel common variants associated with chronic pain using conditional false discovery rate analysis with major depressive disorder and assessment of pleiotropic effects of LRFN5. (PMID:31748543)
• LRFN5 locus structure is associated with autism and influenced by the sex of the individual and locus conversions. (PMID:35088940)
• CircLRFN5 inhibits the progression of glioblastoma via PRRX2/GCH1 mediated ferroptosis. (PMID:36266731)
• LRFN5 and OLFM4 as novel potential biomarkers for major depressive disorder: a pilot study. (PMID:37280213)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	lrfn5a	ENSDARG00000071230
mus_musculus	Lrfn5	ENSMUSG00000035653
rattus_norvegicus	Lrfn5	ENSRNOG00000005550

Paralogs (25): SLITRK3 (ENSG00000121871), LRFN3 (ENSG00000126243), LRFN1 (ENSG00000128011), SLIT2 (ENSG00000145147), LRFN2 (ENSG00000156564), LRRC38 (ENSG00000162494), SLITRK5 (ENSG00000165300), LRTM2 (ENSG00000166159), LINGO1 (ENSG00000169783), LRRN2 (ENSG00000170382), LRRN3 (ENSG00000173114), LRFN4 (ENSG00000173621), LINGO2 (ENSG00000174482), LRRN1 (ENSG00000175928), SLITRK1 (ENSG00000178235), GP5 (ENSG00000178732), SLITRK4 (ENSG00000179542), LRRC55 (ENSG00000183908), SLIT3 (ENSG00000184347), SLITRK6 (ENSG00000184564), SLITRK2 (ENSG00000185985), LRRC70 (ENSG00000186105), SLIT1 (ENSG00000187122), TLR9 (ENSG00000239732), TPBGL (ENSG00000261594)

Protein

Protein identifiers

Leucine-rich repeat and fibronectin type-III domain-containing protein 5 — Q96NI6 (reviewed: Q96NI6)

All UniProt accessions (3): Q96NI6, G3V364, G3V4N1

UniProt curated annotations — full annotation on UniProt →

Function. Cell adhesion molecule that mediates homophilic cell-cell adhesion in a Ca(2+)-independent manner. Promotes neurite outgrowth in hippocampal neurons.

Subunit / interactions. Can form heteromeric complexes with LRFN1, LRFN2, LRFN3 and LFRN4. Able to form homomeric complexes across cell junctions, between adjacent cells. Does not interact with DLG1, DLG2, DLG3 and DLG4.

Subcellular location. Membrane.

Domain organisation. Lacks a cytoplasmic PDZ-binding motif, which has been implicated in function of related LRFN proteins.

Similarity. Belongs to the LRFN family.

RefSeq proteins (4): NP_001317035, NP_001333102, NP_001333104, NP_689660* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR036116	FN3_sf	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050467	LRFN	Family

Pfam: PF13855, PF13927

UniProt features (54 total): strand 13, helix 8, repeat 7, glycosylation site 6, domain 4, compositionally biased region 4, region of interest 2, topological domain 2, sequence conflict 2, turn 2, signal peptide 1, chain 1, disulfide bond 1, transmembrane region 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
5XNQ	X-RAY DIFFRACTION	2.8
5XWS	X-RAY DIFFRACTION	3.08
5XNP	X-RAY DIFFRACTION	3.73
5XWT	X-RAY DIFFRACTION	4.18

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96NI6-F1	74.66	0.49

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 308–357

Glycosylation sites (6): 73, 330, 339, 382, 406, 452

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 137 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, BENPORATH_ES_WITH_H3K27ME3, WHITEHURST_PACLITAXEL_SENSITIVITY, GOBP_INFLAMMATORY_RESPONSE, GOBP_SYNAPSE_ASSEMBLY, GCANCTGNY_MYOD_Q6, GOBP_REGULATION_OF_MACROPHAGE_ACTIVATION, GOCC_CELL_SURFACE, GOBP_REGULATION_OF_CELL_JUNCTION_ASSEMBLY, TGACCTY_ERR1_Q2, CHX10_01, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GGGTGGRR_PAX4_03, CAGCTG_AP4_Q5, GOBP_CELL_CELL_ADHESION

GO Biological Process (4): negative regulation of macrophage activation (GO:0043031), negative regulation of inflammatory response (GO:0050728), synaptic membrane adhesion (GO:0099560), regulation of presynapse assembly (GO:1905606)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): cell surface (GO:0009986), postsynaptic density membrane (GO:0098839), glutamatergic synapse (GO:0098978), GABA-ergic synapse (GO:0098982), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
synapse	2
negative regulation of leukocyte activation	1
macrophage activation	1
regulation of macrophage activation	1
inflammatory response	1
negative regulation of defense response	1
negative regulation of response to external stimulus	1
regulation of inflammatory response	1
synapse organization	1
cell-cell adhesion	1
regulation of synapse assembly	1
presynapse assembly	1
regulation of presynapse organization	1
binding	1
postsynaptic density	1
postsynaptic membrane	1
postsynaptic specialization membrane	1

Protein interactions and networks

STRING

1412 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LRFN5	DLG4	P78352	726
LRFN5	PTPRS	Q13332	694
LRFN5	ANTXR2	P58335	601
LRFN5	IL1RAPL1	Q9NZN1	582
LRFN5	FBXO33	Q7Z6M2	555
LRFN5	FN1	P02751	517
LRFN5	TNFRSF14	Q92956	514
LRFN5	CTNND2	Q9UQB3	506
LRFN5	TJP2	Q9UDY2	488
LRFN5	SYP	P08247	466
LRFN5	RABEPK	Q7Z6M1	459
LRFN5	TRAPPC6B	Q86SZ2	451
LRFN5	LAD1	O00515	444
LRFN5	SHANK3	Q9BYB0	431
LRFN5	FNDC10	F2Z333	428

IntAct

9 interactions, top by confidence:

A	B	Type	Score
LRFN5	PTPRD	psi-mi:“MI:0915”(physical association)	0.540
PTPRF	LRFN5	psi-mi:“MI:0915”(physical association)	0.540
PTPRS	LRFN5	psi-mi:“MI:0915”(physical association)	0.540
PTPRS	LRFN5	psi-mi:“MI:0407”(direct interaction)	0.540
LRFN5	PTPRD	psi-mi:“MI:0407”(direct interaction)	0.540
LRFN5	PTPRF	psi-mi:“MI:0407”(direct interaction)	0.540
BTNL9	LRFN5	psi-mi:“MI:0915”(physical association)	0.400
TLK2	IGKV1D-13	psi-mi:“MI:0914”(association)	0.350

BioGRID (2): LRFN5 (Affinity Capture-RNA), LRFN5 (Affinity Capture-MS)

ESM2 similar proteins: A1XQX1, A1XQX3, A1XQY0, A8WGA3, C6K2K4, D0PRN2, D0PRN4, D4A1J9, E9PUN2, O13097, O42596, O73612, O73874, P0DI97, P52795, P52796, P58400, P58401, P98172, Q01974, Q0PMD2, Q17QD6, Q28142, Q28143, Q460M5, Q63373, Q63376, Q6NW40, Q6PCX7, Q6PFE7, Q7TQ33, Q80TG9, Q8BNJ6, Q8BXA0, Q8C985, Q8IYR6, Q8NC67, Q91590, Q96B86, Q96NI6

Diamond homologs: A0A1Y9G8H0, A0A452E9Y6, A1KZ92, A2A8L5, A2AJ76, A4IFW2, A4IGL7, A4IIW9, A5JUY8, A7MBJ4, A8WGA3, A8WQH2, B0BNK7, B3A0P3, D2HFT7, D3YXG0, D4A1J9, D4ABX8, G5EBF1, G5EG78, H2A0M7, O15146, O35158, O55005, O89026, P05164, P07202, P09933, P0C6S8, P0C7J6, P11247, P11678, P14650, P16621, P22079, P23468, P35419, P49290, P70193, P80025

SIGNOR signaling

6 interactions.

A	Effect	B	Mechanism
LRFN5	up-regulates	Synaptic_plasticity
LRFN5	“up-regulates activity”	PTPRD	binding
LRFN5	“up-regulates activity”	PTPRF	binding
LRFN5	“up-regulates activity”	PTPRS	binding
LRFN5	up-regulates	Neurite_outgrowth

Disease & clinical

Clinical variants and AI predictions

ClinVar

103 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	81
Likely benign	8
Benign	6

Top pathogenic / likely-pathogenic (0)

SpliceAI

2936 predictions. Top by Δscore:

Variant	Effect	Δscore
14:41767027:GAA:G	donor_gain	1.0000
14:41767030:G:GG	donor_gain	1.0000
14:41891249:GA:G	acceptor_gain	1.0000
14:41610224:G:GA	donor_gain	0.9900
14:41639479:T:G	donor_gain	0.9900
14:41766836:T:TA	acceptor_gain	0.9900
14:41766840:T:TA	acceptor_gain	0.9900
14:41766849:T:A	acceptor_gain	0.9900
14:41766852:A:AG	acceptor_gain	0.9900
14:41766853:G:GG	acceptor_gain	0.9900
14:41766853:GA:G	acceptor_gain	0.9900
14:41767028:AAGT:A	donor_loss	0.9900
14:41767029:AGT:A	donor_loss	0.9900
14:41767031:TA:T	donor_loss	0.9900
14:41767032:AAGTT:A	donor_loss	0.9900
14:41891245:CTCAG:C	acceptor_loss	0.9900
14:41891246:TCAGA:T	acceptor_loss	0.9900
14:41891247:CAG:C	acceptor_loss	0.9900
14:41891248:A:AG	acceptor_gain	0.9900
14:41891248:AG:A	acceptor_loss	0.9900
14:41891248:AGAAT:A	acceptor_gain	0.9900
14:41891249:G:GG	acceptor_gain	0.9900
14:41891249:GAAT:G	acceptor_gain	0.9900
14:41891249:GAATG:G	acceptor_gain	0.9900
14:41610223:T:TA	donor_gain	0.9800
14:41680848:G:GT	donor_gain	0.9800
14:41761557:T:TA	acceptor_gain	0.9800
14:41874059:A:G	acceptor_gain	0.9800
14:41876178:A:AG	donor_gain	0.9800
14:41889838:T:TA	donor_gain	0.9800

AlphaMissense

4747 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:41886792:T:C	L56P	1.000
14:41886837:T:C	F71S	1.000
14:41886864:T:C	L80P	1.000
14:41886879:A:T	N85I	1.000
14:41886880:T:A	N85K	1.000
14:41886880:T:G	N85K	1.000
14:41887080:T:C	L152P	1.000
14:41887096:T:A	N157K	1.000
14:41887096:T:G	N157K	1.000
14:41887168:T:A	N181K	1.000
14:41887168:T:G	N181K	1.000
14:41887239:A:T	N205I	1.000
14:41887240:T:A	N205K	1.000
14:41887240:T:G	N205K	1.000
14:41887245:T:C	L207S	1.000
14:41887345:C:A	N240K	1.000
14:41887345:C:G	N240K	1.000
14:41887375:G:C	W250C	1.000
14:41887375:G:T	W250C	1.000
14:41887485:C:A	P287H	1.000
14:41887547:T:A	C308S	1.000
14:41887547:T:C	C308R	1.000
14:41887548:G:C	C308S	1.000
14:41887549:C:G	C308W	1.000
14:41887559:G:A	G312R	1.000
14:41887559:G:C	G312R	1.000
14:41887560:G:A	G312E	1.000
14:41887583:T:A	W320R	1.000
14:41887583:T:C	W320R	1.000
14:41887584:G:C	W320S	1.000

dbSNP variants (sampled 300 via entrez): RS1000032149 (14:41697974 G>A,T), RS1000041305 (14:41772953 C>A,G), RS1000042995 (14:41660142 C>G), RS1000058658 (14:41681824 A>T), RS1000065550 (14:41703982 A>G), RS1000075723 (14:41866111 A>G,T), RS1000089643 (14:41801934 C>G,T), RS1000092589 (14:41615460 T>G), RS1000109398 (14:41694548 C>A), RS1000120041 (14:41744442 G>A), RS1000132746 (14:41685658 G>A), RS1000134769 (14:41850048 C>G,T), RS1000137286 (14:41730148 T>A), RS1000139556 (14:41785107 G>T), RS1000159499 (14:41607864 G>A)

Disease associations

OMIM: gene MIM:612811 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

17 associations (top):

Study	Trait	p-value
GCST001378_1	Hemostatic factors and hematological phenotypes	7.000000e-06
GCST001890_3	QT interval (drug interaction)	5.000000e-06
GCST002828_30	Urate levels in obese individuals	9.000000e-06
GCST002937_6	Molybdenum levels	2.000000e-06
GCST003997_40	Myopia	2.000000e-16
GCST005839_34	Depression	3.000000e-09
GCST006291_102	Spherical equivalent or myopia (age of diagnosis)	1.000000e-19
GCST006485_10	Telomere length	8.000000e-08
GCST006616_5	Uterine fibroid number (single vs multiple)	7.000000e-07
GCST007324_6	Adventurousness	8.000000e-10
GCST007325_165	General risk tolerance (MTAG)	2.000000e-11
GCST007576_183	Chronotype	6.000000e-09
GCST009600_25	Anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy)	2.000000e-08
GCST009863_22	Insulin-related traits (multivariate analysis)	5.000000e-08
GCST010002_149	Refractive error	1.000000e-39
GCST010988_535	Adult body size	2.000000e-09
GCST010988_536	Adult body size	4.000000e-10

EFO canonical traits (10, from GWAS)

EFO ID	Trait name
EFO:0004503	hematological measurement
EFO:0004637	protein S measurement
EFO:0004682	QT interval
EFO:0007922	response to sulfonylurea
EFO:0004531	urate measurement
EFO:0004847	age at onset
EFO:0009410	uterine fibroid measurement
EFO:0008579	risk-taking behaviour
EFO:0008328	chronotype measurement
EFO:0004467	insulin measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	decreases expression	1
bisphenol A	affects cotreatment, increases methylation	1
arsenite	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
dorsomorphin	increases expression, affects cotreatment	1
Resveratrol	decreases expression, affects cotreatment	1
Sunitinib	decreases expression	1
Fulvestrant	increases methylation, affects cotreatment	1
Vorinostat	affects cotreatment, increases expression	1
Acetaminophen	decreases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Cytarabine	decreases expression	1
Lipopolysaccharides	affects response to substance, increases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Rotenone	decreases expression	1
Silicon Dioxide	increases expression	1
Valproic Acid	decreases expression	1
Cyclosporine	decreases expression	1
Aflatoxin B1	decreases methylation	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.